350 related articles for article (PubMed ID: 28205554)
21. Non-canonical roles of PFKFB3 in regulation of cell cycle through binding to CDK4.
Jia W; Zhao X; Zhao L; Yan H; Li J; Yang H; Huang G; Liu J
Oncogene; 2018 Mar; 37(13):1685-1698. PubMed ID: 29335521
[TBL] [Abstract][Full Text] [Related]
22. Pathogenesis of lung cancer signalling pathways: roadmap for therapies.
Brambilla E; Gazdar A
Eur Respir J; 2009 Jun; 33(6):1485-97. PubMed ID: 19483050
[TBL] [Abstract][Full Text] [Related]
23. Mechanisms of growth arrest by c-myc antisense oligonucleotides in MCF-7 breast cancer cells: implications for the antiproliferative effects of antiestrogens.
Carroll JS; Swarbrick A; Musgrove EA; Sutherland RL
Cancer Res; 2002 Jun; 62(11):3126-31. PubMed ID: 12036924
[TBL] [Abstract][Full Text] [Related]
24. Sensitivity of Small Cell Lung Cancer to BET Inhibition Is Mediated by Regulation of ASCL1 Gene Expression.
Lenhart R; Kirov S; Desilva H; Cao J; Lei M; Johnston K; Peterson R; Schweizer L; Purandare A; Ross-Macdonald P; Fairchild C; Wong T; Wee S
Mol Cancer Ther; 2015 Oct; 14(10):2167-74. PubMed ID: 26253517
[TBL] [Abstract][Full Text] [Related]
25. Tumor suppressor LATS1 is a negative regulator of oncogene YAP.
Hao Y; Chun A; Cheung K; Rashidi B; Yang X
J Biol Chem; 2008 Feb; 283(9):5496-509. PubMed ID: 18158288
[TBL] [Abstract][Full Text] [Related]
26. Identification of key candidate genes involved in melanoma metastasis.
Chen J; Wu F; Shi Y; Yang D; Xu M; Lai Y; Liu Y
Mol Med Rep; 2019 Aug; 20(2):903-914. PubMed ID: 31173190
[TBL] [Abstract][Full Text] [Related]
27. The MYC-WDR5 Nexus and Cancer.
Thomas LR; Foshage AM; Weissmiller AM; Tansey WP
Cancer Res; 2015 Oct; 75(19):4012-5. PubMed ID: 26383167
[TBL] [Abstract][Full Text] [Related]
28. The Novel Bromodomain and Extraterminal Domain Inhibitor INCB054329 Induces Vulnerabilities in Myeloma Cells That Inform Rational Combination Strategies.
Stubbs MC; Burn TC; Sparks R; Maduskuie T; Diamond S; Rupar M; Wen X; Volgina A; Zolotarjova N; Waeltz P; Favata M; Jalluri R; Liu H; Liu XM; Li J; Collins R; Falahatpisheh N; Polam P; DiMatteo D; Feldman P; Dostalik V; Thekkat P; Gardiner C; He X; Li Y; Covington M; Wynn R; Ruggeri B; Yeleswaram S; Xue CB; Yao W; Combs AP; Huber R; Hollis G; Scherle P; Liu PCC
Clin Cancer Res; 2019 Jan; 25(1):300-311. PubMed ID: 30206163
[TBL] [Abstract][Full Text] [Related]
29. Cancer network activity associated with therapeutic response and synergism.
Serra-Musach J; Mateo F; Capdevila-Busquets E; de Garibay GR; Zhang X; Guha R; Thomas CJ; Grueso J; Villanueva A; Jaeger S; Heyn H; Vizoso M; Pérez H; Cordero A; Gonzalez-Suarez E; Esteller M; Moreno-Bueno G; Tjärnberg A; Lázaro C; Serra V; Arribas J; Benson M; Gustafsson M; Ferrer M; Aloy P; Pujana MÀ
Genome Med; 2016 Aug; 8(1):88. PubMed ID: 27553366
[TBL] [Abstract][Full Text] [Related]
30. Functional, chemical genomic, and super-enhancer screening identify sensitivity to cyclin D1/CDK4 pathway inhibition in Ewing sarcoma.
Kennedy AL; Vallurupalli M; Chen L; Crompton B; Cowley G; Vazquez F; Weir BA; Tsherniak A; Parasuraman S; Kim S; Alexe G; Stegmaier K
Oncotarget; 2015 Oct; 6(30):30178-93. PubMed ID: 26337082
[TBL] [Abstract][Full Text] [Related]
31. XPO1-dependent nuclear export is a druggable vulnerability in KRAS-mutant lung cancer.
Kim J; McMillan E; Kim HS; Venkateswaran N; Makkar G; Rodriguez-Canales J; Villalobos P; Neggers JE; Mendiratta S; Wei S; Landesman Y; Senapedis W; Baloglu E; Chow CB; Frink RE; Gao B; Roth M; Minna JD; Daelemans D; Wistuba II; Posner BA; Scaglioni PP; White MA
Nature; 2016 Oct; 538(7623):114-117. PubMed ID: 27680702
[TBL] [Abstract][Full Text] [Related]
32. Retinoic acid-mediated growth inhibition of small cell lung cancer cells is associated with reduced myc and increased p27Kip1 expression.
Weber E; Ravi RK; Knudsen ES; Williams JR; Dillehay LE; Nelkin BD; Kalemkerian GP; Feramisco JR; Mabry M
Int J Cancer; 1999 Mar; 80(6):935-43. PubMed ID: 10074929
[TBL] [Abstract][Full Text] [Related]
33. Multiple gene effects in radiation oncogenesis.
Hall EJ
Radiat Res; 2005 Jun; 163(6):697-8. PubMed ID: 16044498
[No Abstract] [Full Text] [Related]
34. Targeting of multiple oncogenic signaling pathways by Hsp90 inhibitor alone or in combination with berberine for treatment of colorectal cancer.
Su YH; Tang WC; Cheng YW; Sia P; Huang CC; Lee YC; Jiang HY; Wu MH; Lai IL; Lee JW; Lee KH
Biochim Biophys Acta; 2015 Oct; 1853(10 Pt A):2261-72. PubMed ID: 25982393
[TBL] [Abstract][Full Text] [Related]
35. MEDICI: Mining Essentiality Data to Identify Critical Interactions for Cancer Drug Target Discovery and Development.
Harati S; Cooper LA; Moran JD; Giuste FO; Du Y; Ivanov AA; Johns MA; Khuri FR; Fu H; Moreno CS
PLoS One; 2017; 12(1):e0170339. PubMed ID: 28118365
[TBL] [Abstract][Full Text] [Related]
36. A CK2-dependent mechanism for degradation of the PML tumor suppressor.
Scaglioni PP; Yung TM; Cai LF; Erdjument-Bromage H; Kaufman AJ; Singh B; Teruya-Feldstein J; Tempst P; Pandolfi PP
Cell; 2006 Jul; 126(2):269-83. PubMed ID: 16873060
[TBL] [Abstract][Full Text] [Related]
37. Functional genomics identifies specific vulnerabilities in PTEN-deficient breast cancer.
Tang YC; Ho SC; Tan E; Ng AWT; McPherson JR; Goh GYL; Teh BT; Bard F; Rozen SG
Breast Cancer Res; 2018 Mar; 20(1):22. PubMed ID: 29566768
[TBL] [Abstract][Full Text] [Related]
38. Targeting the BRD4-HOXB13 Coregulated Transcriptional Networks with Bromodomain-Kinase Inhibitors to Suppress Metastatic Castration-Resistant Prostate Cancer.
Nerlakanti N; Yao J; Nguyen DT; Patel AK; Eroshkin AM; Lawrence HR; Ayaz M; Kuenzi BM; Agarwal N; Chen Y; Gunawan S; Karim RM; Berndt N; Puskas J; Magliocco AM; Coppola D; Dhillon J; Zhang J; Shymalagovindarajan S; Rix U; Kim Y; Perera R; Lawrence NJ; Schonbrunn E; Mahajan K
Mol Cancer Ther; 2018 Dec; 17(12):2796-2810. PubMed ID: 30242092
[TBL] [Abstract][Full Text] [Related]
39. c-Myc regulates cyclin D-Cdk4 and -Cdk6 activity but affects cell cycle progression at multiple independent points.
Mateyak MK; Obaya AJ; Sedivy JM
Mol Cell Biol; 1999 Jul; 19(7):4672-83. PubMed ID: 10373516
[TBL] [Abstract][Full Text] [Related]
40. AZD5153: A Novel Bivalent BET Bromodomain Inhibitor Highly Active against Hematologic Malignancies.
Rhyasen GW; Hattersley MM; Yao Y; Dulak A; Wang W; Petteruti P; Dale IL; Boiko S; Cheung T; Zhang J; Wen S; Castriotta L; Lawson D; Collins M; Bao L; Ahdesmaki MJ; Walker G; O'Connor G; Yeh TC; Rabow AA; Dry JR; Reimer C; Lyne P; Mills GB; Fawell SE; Waring MJ; Zinda M; Clark E; Chen H
Mol Cancer Ther; 2016 Nov; 15(11):2563-2574. PubMed ID: 27573426
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]